Bionano Genomics Inc. (NASDAQ: BNGO) has announced that it has made considerable progress with Spahyr System adoption in China for optical genome mapping through WeHealth Shanghai. WeHealth is a reproductive health genome analysis solutions provider.
Bionanon presents at structural variations symposium.
The company announced the adoption during the Structural Variation Symposium in Shanghai, arranged by the Shanghai Society of Genetics. With optical genome mapping (OGM) paired with whole-genome or whole-exome sequencing, WeHealth has announced the introduction of its entire genome-analysis package.
The symposium featured various scientific presentations covering a range of OGM applications in genome analysis. In addition, several presentations covered reproductive health, which is a significant opportunity and needs in China.
Saphyr system becoming popular.
Bionano Genomics CEO Erik Holmnlin said, “This week’s WeHealth symposium demonstrates the success of our market development efforts in China. We are seeing both a growth in Saphyr adoption and an expansion of its applications. The China market is important in part because it represents one of the world’s largest in reproductive health and genetics. We continue to invest in our commercial operations in China, driven by our new commercial leaders, CCO Jason Priar and China business leader Li Yu. We look forward to seeing continued progress in China as a result of these efforts.”
The Saphyr system is an ultra-specific and ultra-sensitive structural variation identification research-only platform. It allows clinicians and researchers to speed up the search for new treatment targets and diagnostics and expedite cytogenetics research. The system comprises an instrument, reagents, chip consumables, and a collection of data analysis tools. Researchers that do not want to use the Saphyr system in their labs can use Bionano’s genome analysis services to gain access to data generated by the Saphyr system.